SRT3.DE · Intrinsic value
Is Sartorius Aktiengesellschaft (SRT3.DE) overvalued or undervalued?
Sartorius Aktiengesellschaft (SRT3.DE) trades at the delayed market price of €260.70 a share. That price already implies revenue growth of more than 25%/yr. TickerWorth's fair value is €95.62 a share (173% above fair value), as of Oct 19, 2026. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is SRT3.DE overvalued?
- Fair value
- €95.62
- Market price
- €260.70
- Downside to fair value
- 63.3%
- Verdict
- 173% above fair value
Reverse DCF: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is SRT3.DE's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in Europe
Its strongest point: growing quickly. Its weakest: looks expensive on the numbers.
- Value · 5 of 100
Cheaper than 5% of Healthcare companies in Europe
- Price vs worth · 0 of 100
- Quality · 39 of 100
More profitable than 39% of Healthcare companies in Europe
- Financial health · 17 of 100
Financially stronger than 17% of Healthcare companies in Europe
- Growth · 88 of 100
Growing faster than 88% of Healthcare companies in Europe
- Momentum · 81 of 100
Outperformed 81% of Healthcare companies in Europe over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
SRT3.DE DCF valuation: what the price assumes
At a recent price of €260.70, Sartorius Aktiengesellschaft (SRT3.DE) trades 173% above TickerWorth's blended fair value of €95.62 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices SRT3.DE overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -63.3% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values SRT3.DE at about €39.12 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Sartorius Aktiengesellschaft's projected free cash flows at a weighted-average cost of capital (WACC) of 10.9%, with a long-run terminal growth rate of 2.5%. About 68% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — SRT3.DE would need sustained revenue growth of more than 25%/yr to justify today's price, against about 3.5% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, SRT3.DE's modeled DCF value ranges from about €19.82 to €74.44 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Sartorius Aktiengesellschaft would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of SRT3.DE's intrinsic value. Figures update as new filings and prices come in.
Every input behind SRT3.DE's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | €3,581,700,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 18.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 3% → 3% → 4% → 4% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.45 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 69M |
| Market priceDelayed quote · as of 2026-10-19 16:21 UTC | €260.70 |
Change SRT3.DE's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Sartorius Aktiengesellschaft do?
What does it do?
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in Germany. The company employs roughly 14,279 people.
How does it make money?
The business turns 3.6B in annual revenue into profit. Out of every $100 of sales, about $18 is left as operating profit (operating margin of 18.0%), after a 46% gross margin on the products/services it sells. After all costs, taxes and interest, 5.5% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries moderate debt (1.0× equity), can just cover its short-term bills (1.1× current ratio), and is currently profitable.
SRT3.DE insider trading
Insider filings are available for US-listed companies only.
Common questions
What is SRT3.DE's intrinsic value?
TickerWorth's blended fair value for Sartorius Aktiengesellschaft (SRT3.DE) is €95.62 per share, versus a market price of €260.70 (173% above fair value).
Is SRT3.DE overvalued or undervalued?
On our blended fair value SRT3.DE looks overvalued vs fair value at €260.70. This is an educational estimate, not advice.
What discount rate is used for SRT3.DE?
A WACC of 10.9% and a terminal growth rate of 2.5%.
Is Sartorius Aktiengesellschaft stock undervalued?
TickerWorth's fair value for Sartorius Aktiengesellschaft (SRT3.DE) is €95.62 against a market price of €260.70. Our read: 173% above fair value. This is a model estimate, not investment advice.
Sartorius Aktiengesellschaft (SRT3.DE) DCF valuation and fair value
Our fair value for Sartorius Aktiengesellschaft (SRT3.DE) is €95.62, built on a 10.9% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Sartorius Aktiengesellschaft stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of €260.70. A model estimate, not investment advice.
Sartorius Aktiengesellschaft (SRT3.DE) insider trading
We have no recent SEC Form 4 insider filings on file for Sartorius Aktiengesellschaft (SRT3.DE). Form 4 covers US-listed companies only.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.